PHASE-II TRIAL OF ADRIAMYCIN IN THE TREATMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA - GYNECOLOGIC ONCOLOGY GROUP-STUDY

  • 1 January 1979
    • journal article
    • research article
    • Vol. 63  (1) , 21-27
Abstract
Patients (43) with advanced or recurrent endometrial carcinoma no longer amenable to management with surgery or radiotherapy were treated with adriamycin. Of the 43 patients, 16 demonstrated objective response to drug therapy with a .gtoreq. 50% reduction in the size of measurable disease. There were 11 complete responses among the 16 responders. Responders had a significantly better survival than nonresponders (P < 0.05). Initial performance status was the only factor of demonstrable prognostic significance. Toxicity was similar to that observed in other phase II trials of adriamycin. Adriamycin, based on these data, is an active agent in the treatment of advanced or recurrent endometrial carcinoma.

This publication has 1 reference indexed in Scilit: